Drug intelligence / Profile preview

HLK-R035

Development stage: Preclinical
Lead developer: HLK Pharmacin
Modality: Small Molecules

Overview

HLK-R035 is a 505(b)(2) reformulation being developed by Pharmacin International (Shenzhen Pharmacin Co., Ltd) for the treatment of onychomycosis, a fungal infection of the nails. As a 505(b)(2) candidate, it represents a modified version of an existing approved drug, potentially offering improved delivery, efficacy, or safety over the original product. The specific active ingredient and biological target have not been publicly disclosed. The compound is currently in the preclinical or feasibility stage of development.

Beyond the preview

Go deeper on HLK-R035.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLK-R035.

Explore the full profile